Navigation Links
Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
Date:3/23/2009

- Hank Nordhoff, CEO Since 1994, to Serve as Non-Executive Chairman of the Board -

SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that its board of directors has elected Carl W. Hull the Company's new chief executive officer (CEO), effective May 18, 2009. He also is expected to join the Company's board of directors at that time.

Mr. Hull, currently Gen-Probe's president and chief operating officer, will become president and CEO following the retirement of Henry L. Nordhoff as the Company's CEO on May 17, 2009. Mr. Nordhoff, who has served as Gen-Probe's chief executive officer since 1994, will become non-executive chairman upon his re-election to the board by stockholders at the Company's 2009 annual meeting.

"I'm delighted to announce the board's unanimous election of Carl as Gen-Probe's next CEO," Nordhoff said. "He brings unparalleled experience in our field and a deep understanding of molecular diagnostics. His keen intellect and unflagging energy will prove invaluable as he takes the helm of the Company."

"In nearly 15 years as CEO of Gen-Probe, Hank has presided over tremendous business growth, product innovation and shareholder value creation," said Armin Kessler, Gen-Probe's lead independent director and former chief operating officer of Hoffman-La Roche. "The Company has grown from a subsidiary of Chugai, with $61 million in annual revenues, to a public company with a market capitalization exceeding $2 billion and revenues of $473 million last year. Gen-Probe's customers, employees and shareholders owe him a debt of gratitude, and the board is fortunate to be able to continue benefiting from his guidance and leadership."

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release relating to expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements regarding future growth, the composition of the board of directors, and the plans and objectives of management are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks include, but are not limited to, the risk that we cannot retain key executives. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

    Contact:

    Michael Watts
    Vice president, investor relations and corporate communications
    858-410-8673


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tepnel Shareholders Approve Acquisition by Gen-Probe
2. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
3. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
4. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
5. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
6. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
7. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
8. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
9. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
10. Gen-Probe to Webcast Two Upcoming Investor Presentations
11. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... Mediaplanet today ... for organ transplantation while encouraging readers to sign up as an organ donor for ... organ transplant. , An organ donor can save up to 8 saves through ...
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... ... education program through the Pennsylvania Cable Network (PCN) during the summer of 2016. ... Injury Implementation Grant provided by the United States Department of Health and Human ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... for customers and employees that are both engaging and easy to use. Coming ... Technology, the software company revealed today its plans to roll out new AI-powered ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 KEY FINDINGS ... Patient warming and cooling ... during surgeries, lowering the risks of neurological disorders post cardiac ... The patient warming systems can be segmented into convective warming ... turn reduce the stay at hospitals thus, lowering the healthcare ...
(Date:12/8/2016)... KEY FINDINGS The global medical ... Various reasons for growth of the medical lifting sling ... chronic diseases, high recovery cost of injuries and government ... lifting sling refers to an assistive device that helps ... connect to the lift and hold the patient. It ...
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
Breaking Medicine Technology: